Status:
RECRUITING
The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients
Lead Sponsor:
Oslo University Hospital
Collaborating Sponsors:
Loghman-Hakim Hospital, Teheran, Iran
Shohada-e-Tajrish Hospital, Teheran, Iran
Conditions:
Methanol Poisoning
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
The projects investigate if treatment with isocapnic hyperventilation can eliminate methanol from the body in a similar manner to dialysis. This is achieved by administering the antidote (fomepizole) ...
Detailed Description
Isocapnic hyperventilation (iHV) The normal physiology breathing is a careful balance between the number of breaths per minute (rate/min) and the depth of each breath (tidal volume, Vt). Together they...
Eligibility Criteria
Inclusion
- Adult patients, men \& women diagnosed with methanol poisoning
- Serum-methanol ≥ 50 mg/dL (16 mM)
- pH ≥ 7.0, and correctable by bicarbonate infusion
- no (newly developed) visual disturbances
Exclusion
- Acidosis requiring haemodialysis (pH \<7.0), or acidosis that is not responding in spite of aggressive buffer (bicarbonate) treatment within maximum 1-2 hours.
- Comatose patients
- Newly developed visual disturbances
- ADH not fully blocked with antidotes, and not responding to additional dosing of fomepizole. Will be identified by a continuous or increasing anion gap (AG) or Base Excess (BE) on the blood gas machine.
Key Trial Info
Start Date :
December 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06173817
Start Date
December 20 2023
End Date
June 30 2026
Last Update
December 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Loghman-Hakim Hospital,
Tehran, Iran